
Neurotherapeutics Industry Overview: Selected Slides from ISCDD 2012

Starvation Rations in the NeuroGulag



NI Research

Tracking the Future of Neurotherapeutics


Astra Zeneca's Experiment

Inhouse core serving as R&D Frontal Lobe for outsourced activities

Lack of fixed costs means expenditures are more allosteric, activity-dependent. They go up as projects mature and succeed, which is acceptable to AZ

Nontraditional population Phase IIb failures to predict PhIII

Targacept TC-5214
Medivation Dimebon



Academic-Industry 'Partnerships':

All the current rage because they require little upfront or operating funding.

A cheap way to eliminate the small company 'middle man.'

Will the two cultures mesh and work together efficiently and productively? Less often than Big Pharma thinks they will.

NI Research

Bapineuzumab



NI Research

Tracking the Future of Neurotherapeutics

The Search for rapid antidepressant effect....

Naurex's GlyX-13

Depression



NI Research

Dialing down the risk in depression trials....

CeNeRx TriRIMA PhIIb



NI Research

Tracking the Future of Neurotherapeutics

Clinical proof for the cutting-edge....

Ceregene and CERE-120

